# PDUFA dates November 2024: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2024-11

> 249 FDA catalysts are dated in November 2024, including 5 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in November 2024?

PDUFA dates in November 2024: Emrosi (DFD-29, FBIO) on November 4, 2024; AUCATZYL (obecabtagene autoleucel, AUTL) on November 12, 2024; PTC THERAPEUTICS, INC. (PTCT) on November 13, 2024; BridgeBio Pharma, Inc. (BBIO) on November 29, 2024; Attruby (acoramidis, BBIO) on November 29, 2024. [Calendar and source filings](https://sec-api.dev/fda-calendar/2024-11)

Source: SEC Form 10-Q, accession 0001558370-24-015740, https://www.sec.gov/Archives/edgar/data/1429260/000155837024015740/fbio-20240930x10q.htm (retrieved 2026-11-12). Last confirmed 2024-11-14. Cite: https://sec-api.dev/fda-calendar/2024-11#answer

## PDUFA dates in November 2024

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| November 4, 2024 | Fortress Biotech, Inc. | FBIO | Emrosi (DFD-29) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000155837024015740/fbio-20240930x10q.htm) |
| November 12, 2024 | Autolus Therapeutics plc | AUTL | AUCATZYL (obecabtagene autoleucel) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046324000132/autlex-991pr121124.htm) |
| November 13, 2024 | PTC THERAPEUTICS, INC. | PTCT |  |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000012/tmb-20241231x10k.htm) |
| November 29, 2024 | BridgeBio Pharma, Inc. | BBIO |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/bbio-ex99_1.htm) |
| November 29, 2024 | BridgeBio Pharma, Inc. | BBIO | Attruby (acoramidis) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/bbio-ex99_1.htm) |

## All catalysts in November 2024

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 1, 2024 | [Amzeeq® (amzeeq) FDA approval](https://sec-api.dev/pdufa/amzeeq) | DERM |  | completed, approved | "Three of our marketed products, Qbrexza, Amzeeq, and Zilxi as well as Emrosi which was approved by the FDA on November 1, 2024, currently have patent protection." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/derm-20251231x10k.htm)) |
| November 1, 2024 | [MINOCIN® (minocycline) FDA approval](https://sec-api.dev/pdufa/minocycline) | DERM |  | completed, approved | "NDA219015 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20241101, review_priority STANDARD; sponsor_name JOURNEY; product EMROSI (MINOCYCLINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219015%22)) |
| November 4, 2024 | [Emrosi (DFD-29) FDA approval](https://sec-api.dev/pdufa/dfd-29) | DERM | papulopustular rosacea | completed, approved | "Emrosi™ was approved by the FDA in November 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034506/tm269707d1_ex99-1.htm)) |
| November 4, 2024 | [Emrosi (DFD-29) PDUFA date](https://sec-api.dev/pdufa/dfd-29) | FBIO |  | completed, approved | "In March 2024, the FDA accepted the NDA for DFD-29 and set a PDUFA goal date of November 4, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000155837024015740/fbio-20240930x10q.htm)) |
| November 6, 2024 | [Ginkgo Bioworks Holdings, Inc. earnings report](https://sec-api.dev/companies/dna/catalysts) | DNA |  | completed | "Ginkgo Bioworks Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830214/000162828024047276/ex991earningspr.htm)) |
| November 6, 2024 | [CFT8919 trial start](https://sec-api.dev/pdufa/cft8919) | CCCC |  | completed | "On November 6, 2024, we announced that our partner, Betta Pharma, had dosed the first patient in its Phase 1 clinical trial of CFT8919 in Greater China." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1662579/000162828025008433/cccc-20241231.htm)) |
| November 7, 2024 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "SERES THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312524256654/d912869dex991.htm)) |
| November 7, 2024 | [PALI-2108 trial start](https://sec-api.dev/pdufa/pali-2108) | PALI |  | completed | "On November 7, 2024, we commenced the Phase 1 clinical trial of PALI-2108." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000024/pali-20260930.htm)) |
| November 8, 2024 | [Kyverna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kytx/catalysts) | KYTX |  | completed | "Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1994702/000095017024126342/kytx-ex99_1.htm)) |
| November 8, 2024 | [AUCATZYL (obecabtagene autoleucel) FDA approval](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | completed, approved | "On November 8, 2024 the Company was notified by the FDA that the Company has been granted marketing approval for AUCATZYL (obecabtagene autoleucel) for the treatment of adult patients (18 years and older) with r/r B-ALL." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm)) |
| November 8, 2024 | [Mereo BioPharma Group plc earnings report](https://sec-api.dev/companies/mreo/catalysts) | MREO |  | completed | "Mereo BioPharma Reports Third Quarter 2024 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719714/000095017024124598/mreo-ex99_1.htm)) |
| November 8, 2024 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-ex99_1.htm)) |
| November 8, 2024 | [ABEONA THERAPEUTICS INC. NDA/BLA acceptance](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "The FDA notified the Company on November 8, 2024 that the BLA was accepted for review, with an assigned Prescription" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/318306/000149315224045340/form10-q.htm)) |
| November 8, 2024 | [Tecartus (brexucabtagene autoleucel) FDA approval](https://sec-api.dev/pdufa/brexucabtagene-autoleucel) | AUTL | with r/r B-ALL | completed, approved | "On November 8, 2024 the FDA approved the use of obe-cel for the treatment of adults with r/r B-ALL." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000069/ex991autoluannualreporta.htm)) |
| November 8, 2024 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774924034889/ex_747440.htm)) |
| November 11, 2024 | [SPRUCE BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/sprb/catalysts) | SPRB |  | completed | "Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1683553/000095017024124436/sprb-ex99_1.htm)) |
| November 11, 2024 | [KEYTRUDA® (pembrolizumab) trial start](https://sec-api.dev/pdufa/pembrolizumab) | CTXR | recurrent solid tumors | completed | "(Nasdaq: CTOR), today announced promising preliminary results from an ongoing investigator-initiated Phase I clinical trial evaluating the safety and efficacy of a combined regimen of pembrolizumab and LYMPHIR™ (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390024096268/ea022067001ex99-1_citius.htm)) |
| November 11, 2024 | [Moleculin Biotech, Inc. earnings report](https://sec-api.dev/companies/mbrx/catalysts) | MBRX |  | completed | "Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1659617/000143774924034317/ex_745839.htm)) |
| November 11, 2024 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341424000056/mlys3q248kex991.htm)) |
| November 11, 2024 | [Oxylanthanum NDA/BLA acceptance](https://sec-api.dev/pdufa/oxylanthanum) | UNCY |  | completed | "On November 11, 2024, we announced that the FDA has accepted the NDA for OLC and has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1766140/000121390024097118/ea0220114-10q_unicycive.htm)) |
| November 11, 2024 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000095017024125940/lxeo-ex99_1.htm)) |
| November 11, 2024 | [KEYTRUDA® (pembrolizumab) trial start](https://sec-api.dev/pdufa/pembrolizumab) | CTOR | recurrent solid tumors | completed | "On November 11, 2024, Citius Oncology, Inc. issued a press release to announce preliminary results from an ongoing investigator-initiated Phase I clinical trial evaluating the safety and efficacy of a combined regimen of pembrolizumab and LYMPHIR™ (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390024096269/ea0220666-8k_citius.htm)) |
| November 11, 2024 | [Neurogene Inc. interim data readout](https://sec-api.dev/companies/ngne/catalysts) | NGNE |  | completed, positive | "On November 11, 2024, we announced positive interim efficacy clinical data in participants receiving the 1E15 vg dose (n=4 for efficacy data; n=5 for safety data) from the Phase 1/2 clinical trial with a data cut-off date of October 17, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000012/ngne-20241231.htm)) |
| November 11, 2024 | [AYTU BIOPHARMA, INC earnings report](https://sec-api.dev/companies/aytu/catalysts) | AYTU |  | completed | "Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1385818/000143774924034898/ex_722664.htm)) |
| November 12, 2024 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000040/a3q24earningspressrelease2.htm)) |
| November 12, 2024 | [EXICURE, INC. earnings report](https://sec-api.dev/companies/xcur/catalysts) | XCUR |  | completed | "Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1698530/000169853024000116/a8kq32024exhibit991.htm)) |
| November 12, 2024 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000095017024124543/agen-ex99_1.htm)) |
| November 12, 2024 | [BridgeBio Pharma, Inc. earnings report](https://sec-api.dev/companies/bbio/catalysts) | BBIO |  | completed | "BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/bbio-ex99_1.htm)) |
| November 12, 2024 | [ATOSSA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/atos/catalysts) | ATOS |  | completed | "Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1488039/000095017024124655/atos-ex99_1.htm)) |
| November 12, 2024 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465924116493/tm2428099d1_ex99-1.htm)) |
| November 12, 2024 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/a2024q3bhvnltdearningsprex.htm)) |
| November 12, 2024 | [LEXICON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/lxrx/catalysts) | LXRX |  | completed | "The Woodlands, Texas, November 12, 2024 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2024 and provided an update on key corporate milestones." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1062822/000106282224000057/pressreleaseearningsq311-1.htm)) |
| November 12, 2024 | [VERZENIO (abemaciclib) trial start](https://sec-api.dev/pdufa/abemaciclib) | ATOS |  | completed | "Initiation of Combination Trial with Quantum Leap Healthcare Collaborative: Atossa, in collaboration with Quantum Leap Healthcare Collaborative, announced that the first patient was dosed in their clinical trial evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®) as a neoadjuvant treatment for high-risk women with newly diagnosed ER+/HER2- breast cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1488039/000095017024124655/atos-ex99_1.htm)) |
| November 12, 2024 | [LISATA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/lsta/catalysts) | LSTA |  | completed | "Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/320017/000032001724000057/ex991earningsrelease3q24fi.htm)) |
| November 12, 2024 | [Altimmune, Inc. earnings report](https://sec-api.dev/companies/alt/catalysts) | ALT |  | completed | "Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326190/000132619024000047/alt-20241112xex99d1.htm)) |
| November 12, 2024 | [TScan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tcrx/catalysts) | TCRX |  | completed | "TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783328/000095017024124558/tcrx-ex99_1.htm)) |
| November 12, 2024 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "Inc. Announces Q3 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000149315224044930/ex99-1.htm)) |
| November 12, 2024 | [ZEVRA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/zvra/catalysts) | ZVRA |  | completed | "Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434647/000143774924034565/ex_716268.htm)) |
| November 12, 2024 | [PROTHENA CORP PUBLIC LTD CO earnings report](https://sec-api.dev/companies/prta/catalysts) | PRTA |  | completed | "Prothena Reports Third Quarter 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1559053/000155905324000034/exhibit991q32024earningsre.htm)) |
| November 12, 2024 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "WALTHAM, Mass. and BOULDER, Colo., November 12, 2024 - Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000095017024124653/cogt-ex99_1.htm)) |
| November 12, 2024 | [IN8BIO, INC. earnings report](https://sec-api.dev/companies/inab/catalysts) | INAB |  | completed | "IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1740279/000095017024125526/inab-ex99_1.htm)) |
| November 12, 2024 | [Pyxis Oncology, Inc. earnings report](https://sec-api.dev/companies/pyxs/catalysts) | PYXS |  | completed | "Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782223/000095017024124581/pyxs-ex99_1.htm)) |
| November 12, 2024 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000095017024125307/fate-ex99_1.htm)) |
| November 12, 2024 | [VTv Therapeutics Inc. earnings report](https://sec-api.dev/companies/vtvt/catalysts) | VTVT |  | completed | "Exhibit 99.1 vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641489/000164148924000073/vtvt-20240930xexx991pressr.htm)) |
| November 12, 2024 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036124046028/ef20038443_ex99-1.htm)) |
| November 12, 2024 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000095017024125359/artv-ex99_1.htm)) |
| November 12, 2024 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312524255200/d911918dex991.htm)) |
| November 12, 2024 | [SANGAMO THERAPEUTICS, INC earnings report](https://sec-api.dev/companies/sgmoq/catalysts) | SGMOQ |  | completed | "RICHMOND, California, November 12, 2024 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001233/000162828024047099/exhibit-991111224.htm)) |
| November 12, 2024 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097824000088/sdgr-20240930xexx991xscena.htm)) |
| November 12, 2024 | [Bicara Therapeutics Inc. earnings report](https://sec-api.dev/companies/bcax/catalysts) | BCAX |  | completed | "Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023658/000119312524255166/d793839dex991.htm)) |
| November 12, 2024 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000095017024124583/dyn-ex99_1.htm)) |
| November 12, 2024 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm)) |
| November 12, 2024 | [Neumora Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nmra/catalysts) | NMRA |  | completed | "Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1885522/000095017024124563/nmra-ex99_1.htm)) |
| November 12, 2024 | [ROCKWELL MEDICAL, INC. earnings report](https://sec-api.dev/companies/rmti/catalysts) | RMTI |  | completed | "Wixom, Michigan, November 12, 2024 - Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and nine months ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1041024/000162828024046792/rmtiq324earningspr-final8k.htm)) |
| November 12, 2024 | [Tempest Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tpst/catalysts) | TPST |  | completed | "Tempest Reports Third Quarter 2024 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1544227/000095017024125444/tpst-ex99_1.htm)) |
| November 12, 2024 | [Replimune Group, Inc. earnings report](https://sec-api.dev/companies/repl/catalysts) | REPL |  | completed | "MA, November 12, 2024 - Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465924116413/tm2428095d1_ex99-1.htm)) |
| November 12, 2024 | [Ensysce Biosciences, Inc. earnings report](https://sec-api.dev/companies/ensc/catalysts) | ENSC |  | completed | "Biosciences Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1716947/000149315224044760/ex99-1.htm)) |
| November 12, 2024 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948024000040/exhibit991-earningsrelease.htm)) |
| November 12, 2024 | [Tonix Pharmaceuticals Holding Corp. earnings report](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed | "Reports Third Quarter 2024 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937124014466/ex99-01.htm)) |
| November 12, 2024 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774924034557/ex_728719.htm)) |
| November 12, 2024 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942524000037/mirm-20241112xexx991.htm)) |
| November 12, 2024 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184324006284/exh_991.htm)) |
| November 12, 2024 | [OmniAb, Inc. earnings report](https://sec-api.dev/companies/oabi/catalysts) | OABI |  | completed | "OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1846253/000184625324000086/a2024q3ex991.htm)) |
| November 12, 2024 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "ImmunityBio Reports Third-Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611024000109/ibrx-20241112x8kexhibit991.htm)) |
| November 12, 2024 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today provided a business update and announced financial results for the third quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/ea021925801ex99-1_protara.htm)) |
| November 12, 2024 | [PROKIDNEY CORP. earnings report](https://sec-api.dev/companies/prok/catalysts) | PROK |  | completed | "ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850270/000095017024124585/prok-ex99_1.htm)) |
| November 12, 2024 | [Calidi Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/cldi/catalysts) | CLDI |  | completed | "Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855485/000149315224044932/ex99-1.htm)) |
| November 12, 2024 | [SYNLOGIC, INC. earnings report](https://sec-api.dev/companies/sybx/catalysts) | SYBX |  | completed | "Synlogic Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1527599/000095017024125523/sybx-ex99_1.htm)) |
| November 12, 2024 | [Annovis Bio, Inc. earnings report](https://sec-api.dev/companies/anvs/catalysts) | ANVS |  | completed | "Annovis Bio Reports Third Quarter Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465924116086/tm2427939d1_ex99-1.htm)) |
| November 12, 2024 | [Perspective Therapeutics, Inc. earnings report](https://sec-api.dev/companies/catx/catalysts) | CATX |  | completed | "SEATTLE - November 12, 2024 - Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced third quarter financial results for the period ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/728387/000095017024125353/catx-ex99_1.htm)) |
| November 12, 2024 | [Roivant Sciences Ltd. earnings report](https://sec-api.dev/companies/roiv/catalysts) | ROIV |  | completed | "Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1635088/000114036124046015/ef20038392_ex99-1.htm)) |
| November 12, 2024 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000095017024124626/hrtx-ex99_1.htm)) |
| November 12, 2024 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, November 12, 2024 - Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000162828024046856/exhibit991-2024q310xqpr.htm)) |
| November 12, 2024 | [Aura Biosciences, Inc. earnings report](https://sec-api.dev/companies/aura/catalysts) | AURA |  | completed | "Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501796/000095017024125390/aura-ex99_1.htm)) |
| November 12, 2024 | [AUCATZYL (obecabtagene autoleucel) PDUFA date](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | completed, approved | "Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates November 12, 2024 at 7:00 AM EST AUCATZYL® (obecabtagene autoleucel) approved by US FDA on November 8, ahead of target PDUFA date of November 16" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046324000132/autlex-991pr121124.htm)) |
| November 12, 2024 | [ZYNQUISTA® (zynquista) FDA advisory committee meeting](https://sec-api.dev/pdufa/zynquista) | LXRX | type 1 diabetes | completed, positive | "•The Advisory Committee voted 11 to 3 that the benefits of ZYNQUISTA do not outweigh the risks in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD), as defined in the voting question as having estimated glomerular filtration rate (eGFR) >45 to <60 mL/min.1.73 m2 or eGFR >60 mL/min/1.73 m2 and urine albumin-to-creatinine ratio (uACR) > 30mg/g. .As part of the discussion, certain committee members expressed support for sotagliflozin in alternative sub-populations of people with T1D and CKD, where they believed the benefits potentially outweigh the risks." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1062822/000106282224000057/pressreleaseearningsq311-1.htm)) |
| November 12, 2024 | [Serina Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ser/catalysts) | SER |  | completed | "Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708599/000149315224044830/ex99-1.htm)) |
| November 12, 2024 | [AUCATZYL (obecabtagene autoleucel) earnings report](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | completed | "Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates November 12, 2024 at 7:00 AM EST AUCATZYL® (obecabtagene autoleucel) approved by US FDA on November 8, ahead of target PDUFA date of November 16" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046324000132/autlex-991pr121124.htm)) |
| November 12, 2024 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000095017024125384/olma-ex99_1.htm)) |
| November 12, 2024 | [Korro Bio, Inc. earnings report](https://sec-api.dev/companies/krro/catalysts) | KRRO |  | completed | "Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703647/000095017024125347/krro-ex99_1.htm)) |
| November 12, 2024 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "FibroGen Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/fgen-ex99_1.htm)) |
| November 12, 2024 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000095017024125340/eldn-ex99_1.htm)) |
| November 12, 2024 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465924116762/tm2428053d1_ex99-1.htm)) |
| November 12, 2024 | [Compass Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cmpx/catalysts) | CMPX |  | completed | "Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1738021/000117184324006247/exh_991.htm)) |
| November 12, 2024 | [Indaptus Therapeutics, Inc. earnings report](https://sec-api.dev/companies/indp/catalysts) | INDP |  | completed | "Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1857044/000149315224044533/ex99-1.htm)) |
| November 12, 2024 | [Theriva Biologics, Inc. earnings report](https://sec-api.dev/companies/tovx/catalysts) | TOVX |  | completed | "Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465924116420/tm2426982d2_ex99-1.htm)) |
| November 12, 2024 | [Erasca, Inc. earnings report](https://sec-api.dev/companies/eras/catalysts) | ERAS |  | completed | "Erasca Reports Third Quarter 2024 Business Updates and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761918/000095017024125337/eras-ex99_1.htm)) |
| November 12, 2024 | [Prime Medicine, Inc. earnings report](https://sec-api.dev/companies/prme/catalysts) | PRME |  | completed | "Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1894562/000162828024047119/a11-12x2024xpressrelease.htm)) |
| November 12, 2024 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000157688524000096/abos-20241112xexx991.htm)) |
| November 12, 2024 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837024015149/srrk-20241112xex99d1.htm)) |
| November 12, 2024 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "Reports Third Quarter 2024 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465924116346/tm2427736d1_ex99-1.htm)) |
| November 12, 2024 | [Revuforj® (revumenib) topline data readout](https://sec-api.dev/pdufa/revumenib) | SNDX |  | completed, positive | "WALTHAM, Mass., November 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, an oral, small molecule menin inhibitor." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017024124545/sndx-ex99_1.htm)) |
| November 12, 2024 | [IBio, Inc. earnings report](https://sec-api.dev/companies/ibio/catalysts) | IBIO |  | completed | "Exhibit 99.1 iBio Reports Fiscal First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1420720/000142072024000053/ibio-20240930xex99d1.htm)) |
| November 12, 2024 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312524255130/d911553dex991.htm)) |
| November 12, 2024 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000095017024125331/orgo-ex99_1.htm)) |
| November 12, 2024 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000095017024124636/ck0001991792-ex99_1.htm)) |
| November 12, 2024 | [Oric Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/oric/catalysts) | ORIC |  | completed | "ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1796280/000095017024125386/oric-ex99_1.htm)) |
| November 12, 2024 | [REPLIGEN CORP earnings report](https://sec-api.dev/companies/rgen/catalysts) | RGEN |  | completed | "Repligen Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/730272/000119312524255167/d811195dex991.htm)) |
| November 12, 2024 | [DYADIC INTERNATIONAL INC earnings report](https://sec-api.dev/companies/dyai/catalysts) | DYAI |  | completed | "JUPITER, FL / November 12, 2024 (GLOBE NEWSWIRE) Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non- pharmaceutical applications including food, non-food and industrial applications, today announced its financial results for the third quarter of 2024 and highlighted recent Company progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213809/000143774924034551/ex_721715.htm)) |
| November 12, 2024 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000165130824000150/exhibit991-q32024earningsr.htm)) |
| November 12, 2024 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "SHANGHAI & CAMBRIDGE, Mass., November 12, 2024 -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828024046809/zlab-20241112x8kex991.htm)) |
| November 12, 2024 | [KALA BIO, Inc. earnings report](https://sec-api.dev/companies/kala/catalysts) | KALA |  | completed | "KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479419/000155837024015168/kala-20241112xex99d1.htm)) |
| November 12, 2024 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000095017024125376/bolt-ex99_1.htm)) |
| November 12, 2024 | [Xenon Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/xene/catalysts) | XENE |  | completed | "Xenon Reports Q3 2024 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1582313/000095017024125374/xene-ex99_1.htm)) |
| November 12, 2024 | [TherapeuticsMD, Inc. earnings report](https://sec-api.dev/companies/txmd/catalysts) | TXMD |  | completed | "PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED NOVEMBER 12, 2024, ENTITLED "THERAPEUTICSMD ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS"" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/25743/000121390024096804/ea022059301ex99-1_therape.htm)) |
| November 12, 2024 | [Climb Bio, Inc. earnings report](https://sec-api.dev/companies/clym/catalysts) | CLYM |  | completed | "Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768446/000095017024125336/clym-ex99_1.htm)) |
| November 12, 2024 | [Longeveron Inc. earnings report](https://sec-api.dev/companies/lgvn/catalysts) | LGVN |  | completed | "Announces Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1721484/000121390024096799/ea022066501ex99-1_longe.htm)) |
| November 12, 2024 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774924034910/ex_747310.htm)) |
| November 12, 2024 | [Wave Life Sciences, Inc. earnings report](https://sec-api.dev/companies/wve/catalysts) | WVE |  | completed | "Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1631574/000119312524255157/d853532dex991.htm)) |
| November 13, 2024 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent corporate achievements." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465924117691/tm2428324d1_ex99-1.htm)) |
| November 13, 2024 | [Enliven Therapeutics, Inc. earnings report](https://sec-api.dev/companies/elvn/catalysts) | ELVN |  | completed | "Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672619/000095017024126323/elvn-ex99_1.htm)) |
| November 13, 2024 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000165495424014289/drma_ex991.htm)) |
| November 13, 2024 | [Xenetic Biosciences, Inc. earnings report](https://sec-api.dev/companies/xbio/catalysts) | XBIO |  | completed | "Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the third quarter of 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534525/000168316824007929/xenetic_ex9901.htm)) |
| November 13, 2024 | [MeiraGTx Holdings plc earnings report](https://sec-api.dev/companies/mgtx/catalysts) | MGTX |  | completed | "LONDON and NEW YORK, November 13, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, 2024, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1735438/000155837024015441/mgtx-20241113xex99d1.htm)) |
| November 13, 2024 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/sls-202411138xkexhibit991.htm)) |
| November 13, 2024 | [ProPhase Labs, Inc. earnings report](https://sec-api.dev/companies/prph/catalysts) | PRPH |  | completed | "Labs Announces Financial Results for the Three Months Ended September 30, 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/868278/000149315224045123/ex99-1.htm)) |
| November 13, 2024 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000095017024125933/ck0001534133-ex99_1.htm)) |
| November 13, 2024 | [Kebilidi (eladocagene exuparvovec) FDA approval](https://sec-api.dev/pdufa/eladocagene-exuparvovec) | PTCT | children and adults with AADC deficiency | completed, approved | "PTC was granted the PRV on November 13, 2024 along with the U.S. Food and Drug Administration (FDA) approval of KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of children and adults with AADC deficiency, including the full spectrum of disease severity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008124000026/tmb-20241126xex99d1.htm)) |
| November 13, 2024 | [HARROW, INC. earnings report](https://sec-api.dev/companies/hrow/catalysts) | HROW |  | completed | "Announces Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1360214/000149315224045283/ex99-1.htm)) |
| November 13, 2024 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000110465924117682/tm2428220d1_ex99-1.htm)) |
| November 13, 2024 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000095017024126288/eq-ex99_1.htm)) |
| November 13, 2024 | [INTEGRATED BIOPHARMA INC earnings report](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | completed | "HILLSIDE, NEW JERSEY (November 13, 2024) - Integrated BioPharma, Inc. (OTCQX: INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1016504/000143774924035331/ex_746768.htm)) |
| November 13, 2024 | [IRulya Therapeutics Inc. earnings report](https://sec-api.dev/companies/irla/catalysts) | IRLA |  | completed | "Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1662774/000166277424000010/exhibit991-q324.htm)) |
| November 13, 2024 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000095017024126382/stro-ex99_1.htm)) |
| November 13, 2024 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000095017024125869/gyre-ex99_1.htm)) |
| November 13, 2024 | [AEON Biopharma, Inc. earnings report](https://sec-api.dev/companies/aeon/catalysts) | AEON |  | completed | "AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760724000092/aeon-20241113xex99.htm)) |
| November 13, 2024 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774924034897/ex_716497.htm)) |
| November 13, 2024 | [INTENSITY THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ints/catalysts) | INTS |  | completed | "Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567264/000156726424000053/ints20241113ex99120240930p.htm)) |
| November 13, 2024 | [Acrivon Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrv/catalysts) | ACRV |  | completed | "Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781174/000095017024125920/acrv-ex99_1.htm)) |
| November 13, 2024 | [PTC THERAPEUTICS, INC. PDUFA date](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | scheduled | "The application was granted priority review with a target regulatory action date of November 13, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000012/tmb-20241231x10k.htm)) |
| November 13, 2024 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs, today announced financial results and business highlights for the quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036124046314/ef20038398_ex99-1.htm)) |
| November 13, 2024 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "13, 2024 - Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the "Company" or "Unicycive"), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended September 30, 2024, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390024097145/ea022088901ex99-1_unicycive.htm)) |
| November 13, 2024 | [Cocrystal Pharma, Inc. earnings report](https://sec-api.dev/companies/cocp/catalysts) | COCP |  | completed | "Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000149315224045083/ex99-1.htm)) |
| November 13, 2024 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS Third QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774924034668/ex_714259.htm)) |
| November 13, 2024 | [Metagenomi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mgx/catalysts) | MGX |  | completed | "Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785279/000095017024126317/mgx-ex99_1.htm)) |
| November 13, 2024 | [X4 Pharmaceuticals, Inc earnings report](https://sec-api.dev/companies/xfor/catalysts) | XFOR |  | completed | "X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501697/000162828024047406/a991pressreleasedatednovem.htm)) |
| November 13, 2024 | [Acurx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/acxp/catalysts) | ACXP |  | completed | "Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1736243/000110465924117214/tm2428175d1_ex99-1.htm)) |
| November 13, 2024 | [Taysha Gene Therapies, Inc. earnings report](https://sec-api.dev/companies/tsha/catalysts) | TSHA |  | completed | "Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806310/000119312524257205/d877348dex991.htm)) |
| November 13, 2024 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979024000127/exhibit991tarsus11132024pr.htm)) |
| November 13, 2024 | [WEZLANA® (ustekinumab) FDA approval](https://sec-api.dev/pdufa/ustekinumab) | ALVO |  | completed, approved | "Alvotech and Teva Pharmaceuticals announced that the U.S. FDA has approved a new presentation of SELARSDI (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), in a 130 mg/26 mL single-dose vial for intravenous infusion." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184324006347/exh_991.htm)) |
| November 13, 2024 | [4D Molecular Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fdmt/catalysts) | FDMT |  | completed | "4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650648/000095017024126346/fdmt-ex99_1.htm)) |
| November 13, 2024 | [Jaguar Health, Inc. earnings report](https://sec-api.dev/companies/jagx/catalysts) | JAGX |  | completed | "Jaguar Health Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585608/000095017024125954/jagx-ex99_1.htm)) |
| November 13, 2024 | [VERZENIO (abemaciclib) label expansion decision](https://sec-api.dev/pdufa/abemaciclib) | LLY |  | completed, approved | "NDA208716 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20241113, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22)) |
| November 13, 2024 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000110465924117704/tm2428191d1_ex99-1.htm)) |
| November 13, 2024 | [Adaptimmune Therapeutics PLC earnings report](https://sec-api.dev/companies/adapy/catalysts) | ADAPY |  | completed | "PHILADELPHIA, PA. and OXFORD, UK, November 13, 2024 - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the third quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1621227/000155837024015525/adap-20241113xex99d1.htm)) |
| November 13, 2024 | [TENAX THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/tenx/catalysts) | TENX |  | completed | "Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/34956/000165495424014203/tenx_ex991.htm)) |
| November 13, 2024 | [Anebulo Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/aneb/catalysts) | ANEB |  | completed | "Texas (November 13, 2024) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended September 30, 2024, and recent updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815974/000149315224045133/ex99-1.htm)) |
| November 13, 2024 | [BioCardia, Inc. earnings report](https://sec-api.dev/companies/bcda/catalysts) | BCDA |  | completed | "BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/925741/000143774924034906/ex_747348.htm)) |
| November 13, 2024 | [CYPHERPUNK TECHNOLOGIES INC. earnings report](https://sec-api.dev/companies/cyph/catalysts) | CYPH |  | completed | "- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509745/000110465924117217/tm2428221d1_ex99-1.htm)) |
| November 13, 2024 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017024125921/spry-ex99_1.htm)) |
| November 13, 2024 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774924034900/ex_711279.htm)) |
| November 13, 2024 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315224045205/ex99-1.htm)) |
| November 13, 2024 | [Instil Bio, Inc. earnings report](https://sec-api.dev/companies/til/catalysts) | TIL |  | completed | "Instil Bio Reports Third Quarter 2024 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789769/000178976924000100/q3-24er.htm)) |
| November 13, 2024 | [Fulcrum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fulc/catalysts) | FULC |  | completed | "Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680581/000095017024125927/fulc-ex99_1.htm)) |
| November 13, 2024 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034024000078/imrx-20241113xexx991.htm)) |
| November 13, 2024 | [DiaMedica Therapeutics Inc. earnings report](https://sec-api.dev/companies/dmac/catalysts) | DMAC |  | completed | "DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401040/000143774924034922/ex_747437.htm)) |
| November 13, 2024 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces Third Quarter 2024 Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000155837024015526/armp-20241113xex99d1.htm)) |
| November 13, 2024 | [AN2 Therapeutics, Inc. earnings report](https://sec-api.dev/companies/antx/catalysts) | ANTX |  | completed | "AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1880438/000095017024126276/antx-ex99_1.htm)) |
| November 13, 2024 | [COGNITION THERAPEUTICS INC earnings report](https://sec-api.dev/companies/cgtx/catalysts) | CGTX |  | completed | "Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1455365/000110465924117243/tm2428074d1_ex99-1.htm)) |
| November 13, 2024 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465924117193/tm2428261d1_ex99-1.htm)) |
| November 13, 2024 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837024015519/capr-20241113xex99d1.htm)) |
| November 13, 2024 | [Passage BIO, Inc. earnings report](https://sec-api.dev/companies/pasg/catalysts) | PASG |  | completed | "PASSAGE BIO REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787297/000155837024015429/pasg-20241113xex99d1.htm)) |
| November 13, 2024 | [TALPHERA, INC. earnings report](https://sec-api.dev/companies/tlph/catalysts) | TLPH |  | completed | "Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1427925/000143774924034907/ex_747071.htm)) |
| November 13, 2024 | [Elicio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eltx/catalysts) | ELTX |  | completed | "Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148524000074/q3earnings_prx11-12x24xf.htm)) |
| November 14, 2024 | [Dare Bioscience, Inc. earnings report](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed | "Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000149315224045860/ex99-1.htm)) |
| November 14, 2024 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572624000053/ino-93024x8kex991.htm)) |
| November 14, 2024 | [BioAffinity Technologies, Inc. earnings report](https://sec-api.dev/companies/biaf/catalysts) | BIAF |  | completed | "ANTONIO, Texas (November 14, 2024) - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1712762/000149315224045422/ex99-1.htm)) |
| November 14, 2024 | [Vyome Holdings, Inc earnings report](https://sec-api.dev/companies/hind/catalysts) | HIND |  | completed | "ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1427570/000155837024015734/rsls-20241114xex99d1.htm)) |
| November 14, 2024 | [CV Sciences, Inc. earnings report](https://sec-api.dev/companies/cvsi/catalysts) | CVSI |  | completed | "CV Sciences, Inc. Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1510964/000095017024126787/cvsi-ex99_1.htm)) |
| November 14, 2024 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "ArriVent BioPharma Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000155837024015622/avbp-20241114xex99d1.htm)) |
| November 14, 2024 | [NRX Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/nrxp/catalysts) | NRXP |  | completed | "WILMINGTON, DE., November 14, 2024 - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year to date ended September 30, 2024 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719406/000143774924035521/ex_748946.htm)) |
| November 14, 2024 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "CAMBRIDGE, Mass., November 14, 2024  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312524258540/d915138dex991.htm)) |
| November 14, 2024 | [Kodiak Sciences Inc. earnings report](https://sec-api.dev/companies/kod/catalysts) | KOD |  | completed | "Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000095017024127029/kod-ex99_1.htm)) |
| November 14, 2024 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000095017024126759/cadl-ex99_1.htm)) |
| November 14, 2024 | [Benitec Biopharma Inc. earnings report](https://sec-api.dev/companies/bntc/catalysts) | BNTC |  | completed | "platform, today announced financial results for its first fiscal quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1808898/000119312524258694/d879713dex991.htm)) |
| November 14, 2024 | [MiNK Therapeutics, Inc. earnings report](https://sec-api.dev/companies/inkt/catalysts) | INKT |  | completed | "MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840229/000117184324006360/exh_991.htm)) |
| November 14, 2024 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774924035391/ex_748171.htm)) |
| November 14, 2024 | [PALATIN TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/ptn/catalysts) | PTN |  | completed | "Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/911216/000165495424014334/ptn_ex991.htm)) |
| November 14, 2024 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Reports Third Quarter 2024 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465924118342/tm2428394d1_ex99-1.htm)) |
| November 14, 2024 | [Rein Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rntx/catalysts) | RNTX |  | completed | "Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1420565/000119312524258568/d912402dex991.htm)) |
| November 14, 2024 | [Faeth Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fth/catalysts) | FTH |  | completed | "Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1829802/000119312524258006/d855965dex991.htm)) |
| November 14, 2024 | [Cue Biopharma, Inc. earnings report](https://sec-api.dev/companies/cue/catalysts) | CUE |  | completed | "Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000095017024127004/cue-ex99_1.htm)) |
| November 14, 2024 | [ABVC BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/abvc/catalysts) | ABVC |  | completed | "ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the third quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1173313/000121390024097894/ea022114301ex99-1_abvcbio.htm)) |
| November 14, 2024 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465924119041/tm2428354d1_ex99-1.htm)) |
| November 14, 2024 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315224046001/ex99-1.htm)) |
| November 14, 2024 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315224045338/ex99-1.htm)) |
| November 14, 2024 | [PRECIGEN, INC. earnings report](https://sec-api.dev/companies/pgen/catalysts) | PGEN |  | completed | "Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2024 financial results and business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1356090/000095010324016317/dp220702_ex9901.htm)) |
| November 14, 2024 | [Biologics earnings report](https://sec-api.dev/pdufa/biologics) | HCWB |  | completed | "Miramar, FL- November 14, 2024 - HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1828673/000095017024127195/hcwb-ex99_1.htm)) |
| November 14, 2024 | [Traws Pharma, Inc. earnings report](https://sec-api.dev/companies/traw/catalysts) | TRAW |  | completed | "2024 (GLOBE NEWSWIRE) -Traws Pharma, Inc. ("Traws" or "Traws Pharma"), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases, today outlined recent business updates and reported unaudited financial results for the third quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1130598/000110465924119064/tm2428509d1_ex99-1.htm)) |
| November 14, 2024 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000095017024126753/rani-ex99_1.htm)) |
| November 14, 2024 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837024015726/fbio-20241114xex99.htm)) |
| November 14, 2024 | [Emavusertib earnings report](https://sec-api.dev/pdufa/emavusertib) | CRIS |  | completed | "LEXINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1108205/000110820524000071/a3q24earningspressrelease.htm)) |
| November 14, 2024 | [Phio Pharmaceuticals Corp. earnings report](https://sec-api.dev/companies/phio/catalysts) | PHIO |  | completed | "Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1533040/000168316824008118/phio_ex9901.htm)) |
| November 14, 2024 | [PDS Biotechnology Corp earnings report](https://sec-api.dev/companies/pdsb/catalysts) | PDSB |  | completed | "PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472091/000114036124046731/ef20038649_ex99-1.htm)) |
| November 14, 2024 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Biosciences Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791924000060/exhibit99109302024.htm)) |
| November 14, 2024 | [Annexon, Inc. earnings report](https://sec-api.dev/companies/annx/catalysts) | ANNX |  | completed | "Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1528115/000095017024127027/annx-ex99_1.htm)) |
| November 14, 2024 | [Arazlo® (tazarotene) earnings report](https://sec-api.dev/pdufa/tazarotene) | GRI |  | completed | "GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429324000153/ex991_pressreleaseq32024ea.htm)) |
| November 14, 2024 | [Valion Bio, Inc. earnings report](https://sec-api.dev/companies/vbio/catalysts) | VBIO |  | completed | "Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787740/000095017024127045/tivc-ex99_1.htm)) |
| November 14, 2024 | [AVENUE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/atxi/catalysts) | ATXI |  | completed | "Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1644963/000143774924035304/ex_748191.htm)) |
| November 14, 2024 | [SENTI-202 trial start](https://sec-api.dev/pdufa/senti-202) | SNTI | relapsed/refractory hematologic malignancies | completed | "SENTI-202 for Acute Myeloid Leukemia ("AML"): The Company announced that patient dosing has commenced, and is ongoing, in the Phase 1 clinical trial of SENTI-202 (NCT06325748) for the treatment of relapsed/refractory hematologic malignancies including AML." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000185427024000114/a20241114ex991earningsrele.htm)) |
| November 14, 2024 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312524257993/d894288dex991.htm)) |
| November 14, 2024 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000155837024015632/pmn-20241114xex99d1.htm)) |
| November 14, 2024 | [Cabaletta Bio, Inc. earnings report](https://sec-api.dev/companies/caba/catalysts) | CABA |  | completed | "Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759138/000095017024126731/caba-ex99_1.htm)) |
| November 14, 2024 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000155837024015705/ganx-20241114xex99d1.htm)) |
| November 14, 2024 | [BioXcel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/btaiq/catalysts) | BTAIQ |  | completed | "Therapeutics Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465924118261/tm2428378d1_ex99-1.htm)) |
| November 14, 2024 | [Eftilagimod trial start](https://sec-api.dev/pdufa/eftilagimod) | IMMP |  | completed | "Company), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive data from the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha (efti) in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer (1L NSCLC) patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506184/000119312524258949/d770422dex991.htm)) |
| November 14, 2024 | [Marker Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mrkr/catalysts) | MRKR |  | completed | "Reports Third Quarter 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1094038/000110465924119077/tm2421372d1_ex99-1.htm)) |
| November 14, 2024 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today reported financial results for the third quarter ended September 30, 2024 and provided recent business highlights, including an update on the Phase 3 registrational program for AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) in development for wet age-related macular degeneration (wet AMD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465924118284/tm2428320d2_ex99-1.htm)) |
| November 14, 2024 | [Silexion Therapeutics Corp earnings report](https://sec-api.dev/companies/slxn/catalysts) | SLXN |  | completed | "14, 2024 - Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for the third quarter ended September 30, 2024, and provided an update on recent business developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022416/000117891324003695/exhibit_99-1.htm)) |
| November 14, 2024 | [Lineage Cell Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lctx/catalysts) | LCTX |  | completed | "LINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/876343/000095017024127058/lctx-ex99_1.htm)) |
| November 14, 2024 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, November 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2024, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000155837024015608/plx-20241114xex99d1.htm)) |
| November 14, 2024 | [ELUTIA INC. earnings report](https://sec-api.dev/companies/elut/catalysts) | ELUT |  | completed | "Elutia Announces Strong Third Quarter Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708527/000110465924118906/tm2428517d1_ex99-1.htm)) |
| November 14, 2024 | [Senti Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/snti/catalysts) | SNTI |  | completed | "Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000185427024000114/a20241114ex991earningsrele.htm)) |
| November 14, 2024 | [Allarity Therapeutics, Inc. earnings report](https://sec-api.dev/companies/allr/catalysts) | ALLR |  | completed | "Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1860657/000143774924035040/ex_748043.htm)) |
| November 14, 2024 | [Enveric Biosciences, Inc. earnings report](https://sec-api.dev/companies/envb/catalysts) | ENVB |  | completed | "Mass., November 14, 2024 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/890821/000149315224045840/ex99-1.htm)) |
| November 14, 2024 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "Biosciences Announces Financial Results for the Third Quarter of 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000149315224046043/ex99-1.htm)) |
| November 14, 2024 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036124046728/ef20038321_ex99-1.htm)) |
| November 14, 2024 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000168036724000050/sttk_q32024earningsrelease.htm)) |
| November 15, 2024 | [Reproxalap NDA/BLA acceptance](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease | completed | "Release") to announce the Extension Letter and that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's resubmitted New Drug Application (NDA) for reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease, and has assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000121390024099333/ea0221568-8k_aldeyra.htm)) |
| November 15, 2024 | [OS Therapies Inc earnings report](https://sec-api.dev/companies/ostx/catalysts) | OSTX |  | completed | "OS Therapies, Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported financial results for the third quarter of 2024 ended September 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1795091/000121390024099094/ea022141701ex99-1_osthera.htm)) |
| November 15, 2024 | [Revuforj® (revumenib) FDA approval](https://sec-api.dev/pdufa/revumenib) | SNDX | To treat relapsed or refractory acute leukemia | completed, approved | "Revuforj \| revumenib \| 11/15/2024 \| To treat relapsed or refractory acute leukemiaDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| November 18, 2024 | [Twist Bioscience Corp earnings report](https://sec-api.dev/companies/twst/catalysts) | TWST |  | completed | "Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581280/000162828024048173/twst-20240930xex991.htm)) |
| November 18, 2024 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465924119941/tm2428692d1_ex99-1.htm)) |
| November 18, 2024 | [ICOTYDE (icotrokinra) topline data readout](https://sec-api.dev/pdufa/icotrokinra) | PTGX |  | completed, positive | "Calif. - November 18, 2024 - Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced positive topline results from its collaboration with Johnson & Johnson, in ICONIC-LEAD1 and ICONIC-TOTAL2, two pivotal Phase 3 investigational studies of icotrokinra (JNJ-2113, formerly PN-235), the first-in-class targeted oral peptide that selectively blocks the IL-23 receptor, in individuals 12 years of age and older with moderate to severe plaque psoriasis (PsO)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465924120165/tm2428765d1_ex99-1.htm)) |
| November 18, 2024 | [ADI-001 trial start](https://sec-api.dev/pdufa/adi-001) | ACET |  | completed | "On November 18, 2024 the Company also announced the first patient dosed in the Phase 1 clinical trial evaluating ADI-001 in lupus nephritis." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1720580/000095017024127927/acet-20241118.htm)) |
| November 18, 2024 | [ELITE PHARMACEUTICALS INC /NV/ FDA approval](https://sec-api.dev/companies/eltp/catalysts) | ELTP | Attention | completed, approved | "November 18, 2024, the Company received approval from the FDA for Lisdex Capsules, a product indicated for the treatment of Attention" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm)) |
| November 18, 2024 | [Neurogene earnings report](https://sec-api.dev/pdufa/neurogene) | NGNE |  | completed | "Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404644/000140464424000103/ngne_3q24release.htm)) |
| November 18, 2024 | [Aldeyra Therapeutics, Inc. NDA/BLA acceptance](https://sec-api.dev/companies/aldx/catalysts) | ALDX |  | completed | "On November 18, 2024, we announced that the FDA had accepted for review the Resubmitted NDA and assigned a PDUFA date of April 2, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1341235/000095017025071602/aldx-20250331.htm)) |
| November 20, 2024 | [NewAmsterdam Pharma Co N.V. topline data readout](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed, positive | "On November 20, 2024, we announced positive topline data from our Phase 3 TANDEM clinical trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1936258/000095017025027339/nams-20241231.htm)) |
| November 20, 2024 | [Mipletamig trial start](https://sec-api.dev/pdufa/mipletamig) | APVO |  | completed | "On November 20, 2024, Aptevo Therapeutics Inc. ("Aptevo" or the "Company") announced that the first patient dosed in Aptevo's ongoing RAINIER trial achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, supporting the continued overall efficacy trend seen in prior mipletamig AML studies." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1671584/000095017024129018/apvo-20241120.htm)) |
| November 20, 2024 | [CytoMed Therapeutics Ltd trial start](https://sec-api.dev/companies/gdtc/catalysts) | GDTC | blood and solid cancers | completed | "November 20 2024 — Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of blood and solid cancers, is pleased to announce that the first patient has been dosed in its first-in-human Phase I dose-escalation clinical trial (NCT05302037)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1873093/000149315224046929/ex99-1.htm)) |
| November 20, 2024 | [ONUREG (azacitidine) trial start](https://sec-api.dev/pdufa/azacitidine) | APVO | Acute Myeloid Leukemia | completed | "Seattle, Washington, November 20, 2024 - Aptevo Therapeutics ("Aptevo") (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today expanded on the potential of mipletamig, currently being evaluated as frontline therapy for the treatment of Acute Myeloid Leukemia (AML), in combination with standard of care venetoclax and azacitidine, noting the first patient dosed in the ongoing RAINIER trial achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000095017024129018/apvo-ex99_1.htm)) |
| November 20, 2024 | [Ziihera® (zanidatamab) FDA approval](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | with previously treated, unresectable or metastatic HER2-positive | completed, approved | "On November 20, 2024, Jazz Pharmaceuticals plc (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") accelerated approval of Ziihera®(zanidatamab-hrii) 50mg/mL for injection for IV for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1232524/000119312524262940/d832756d8k.htm)) |
| November 20, 2024 | [Septerna, Inc. earnings report](https://sec-api.dev/companies/sepn/catalysts) | SEPN |  | completed | "Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1984086/000119312524262539/d888285dex991.htm)) |
| November 21, 2024 | [Camp4 Therapeutics Corp earnings report](https://sec-api.dev/companies/camp/catalysts) | CAMP |  | completed | "CAMBRIDGE, Mass., November 21, 2024 - CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1736730/000110465924121533/tm2428967d1_ex99-1.htm)) |
| November 21, 2024 | [Epilepsy trial start](https://sec-api.dev/pdufa/epilepsy) | QURE | refractory mTLE | completed | "Lexington, MA and Amsterdam, the Netherlands, November 21, 2024 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000155837024015883/qure-20241121xex99d1.htm)) |
| November 21, 2024 | [Vusolimogene oderparepvec NDA/BLA submission](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL |  | completed | "2024 - Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it has submitted a biologics license application (BLA) to the FDA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465924121616/tm2429181d1_ex99-1.htm)) |
| November 22, 2024 | [Beyonttra (beyonttra) FDA approval](https://sec-api.dev/pdufa/beyonttra) | BBIO |  | completed, approved | ""Business" of this Annual Report on Form 10-K, we currently have one commercial product, AttrubyTM that received FDA approval on November 22, 2024 and Beyonttra that received approval from the EC on February 10, 2025, and multiple product candidates in late-stage development." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1743881/000095017025024119/bbio-20241231.htm)) |
| November 22, 2024 | [Attruby (acoramidis) FDA approval](https://sec-api.dev/pdufa/acoramidis) | BBIO | To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis | completed, approved | "Attruby \| acoramidis \| 11/22/2024 \| To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosisDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| November 22, 2024 | [Pretomanid (pretomanid) label expansion decision](https://sec-api.dev/pdufa/pretomanid) | VTRS |  | completed, approved | "NDA212862 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20241122, review_priority STANDARD; sponsor_name MYLAN IRELAND LTD; product PRETOMANID (PRETOMANID)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212862%22)) |
| November 22, 2024 | [Tecvayli (teclistamab-cqyv) label expansion decision](https://sec-api.dev/pdufa/teclistamab-cqyv) | JNJ |  | completed, approved | "BLA761291 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20241122, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product TECVAYLI (TECLISTAMAB-CQYV)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761291%22)) |
| November 25, 2024 | [Simufilam topline data readout](https://sec-api.dev/pdufa/simufilam) | FLNA |  | completed, missed | "On November 25, 2024, we announced that the top-line results from the Phase 3 RETHINK-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1069530/000143774925005919/sava20241231c_10k.htm)) |
| November 25, 2024 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000095017024130553/enta-ex99_1.htm)) |
| November 25, 2024 | [Yeztugo® (lenacapavir) label expansion decision](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed, approved | "NDA215974 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20241125, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product SUNLENCA (LENACAPAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215974%22)) |
| November 26, 2024 | [Valneva SE FDA approval](https://sec-api.dev/companies/valn/catalysts) | VALN |  | completed, approved | "4 Valneva Announces U.S. FDA Approval of World's" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000117184324006606/exh_991.htm)) |
| November 26, 2024 | [ARROWHEAD PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/arwr/catalysts) | ARWR |  | completed | "Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000162828024049281/arwr-202411268kex991.htm)) |
| November 27, 2024 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA215256 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20241127, review_priority STANDARD; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22)) |
| November 29, 2024 | [BridgeBio Pharma, Inc. PDUFA date](https://sec-api.dev/companies/bbio/catalysts) | BBIO |  | scheduled | "November 29, 2024 PDUFA date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/bbio-ex99_1.htm)) |
| November 29, 2024 | [Attruby (acoramidis) PDUFA date](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | completed, approved | "Based on the positive results from ATTRibute-CM, BridgeBio filed a new drug application (NDA) to the FDA, which has been accepted with a PDUFA action date of November 29, 2024, and the late cycle meeting with the FDA has been completed." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/bbio-ex99_1.htm)) |

Other months: https://sec-api.dev/fda-calendar/2024-12. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates November 2024: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2024-11

```bibtex
@misc{secapidev_fda_calendar_2024_11_20261116,
  title        = {PDUFA dates November 2024: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2024-11}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2024_11_20261116","title":"PDUFA dates November 2024: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2024-11","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
